New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:37 EDTADMSAdamas Pharmaceuticals presents positive results from ADS-5102 study
Adamas Pharmaceuticals presented data on the rater and subject training process utilized in the Phase 2/3 EASED safety and efficacy study of ADS-5102 for the treatment of levodopa-induced dyskinesia, a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals with Parkinson's disease unable to perform routine daily tasks. The Phase 2/3 EASED study met its primary endpoint and the efficacy results of ADS-5102 were aligned across all outcome measures. In addition, ADS-5102 was generally well tolerated with reported adverse events consistent with Parkinson's disease and the known amantadine safety profile.
News For ADMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
06:05 EDTADMSAdamas Pharmaceuticals files to sell $150M in common stock, 1.6M for holders
Subscribe for More Information
May 13, 2015
16:39 EDTADMSAdamas Pharmaceuticals sees Namzaric launching in coming months
During its Q1 earnings report, Adamas (ADMS) stated, "In the coming months, we look forward to expanding our wholly-owned product pipeline with the initiation of a phase 2 clinical trial of ADS-5102 for a second CNS-related indication, completing enrollment in one of two ongoing phase 3 trials assessing ADS-5102 for the treatment of LID, and the U.S. launch of Namzaric by our collaborator, Actavis (ACT)."
16:03 EDTADMSAdamas Pharmaceuticals reports Q1 EPS (69c), consensus (74c)
Reports Q1 revenue $226,000 vs. $176,000 last year. Reports $145M in cash, cash equivalents, and marketable securities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use